Academic
Publications
Mammalian target of rapamycin as a target in hematological malignancies

Mammalian target of rapamycin as a target in hematological malignancies,10.1007/s11523-011-0175-8,Targeted Oncology,Kevin R. Kelly,Julie H. Rowe,Swami

Mammalian target of rapamycin as a target in hematological malignancies   (Citations: 3)
BibTex | RIS | RefWorks Download
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
Journal: Targeted Oncology - TARGET ONCOL , vol. 6, no. 1, pp. 53-61, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...The two-part series also highlights the clinical results achieved with TOR inhibitors in patients with a variety of advanced cancers to date including: renal cancer as reviewed by Kumar Pal and Figlin [29], hematopoietic and lymphoid malignancies as reviewed by Kelly et al. [30], soft tissue sarcoma as reviewed by Vemulapalli et al. [31], pediatric malignancies as reviewed by Cam and Houghton [14] and various other relevant ...

    Eric K. Rowinsky. Targeting the target of rapamycin (TOR): looking to mother nature

Sort by: